Category: Synthes Inc.Syndicate content

Judge: Ex-Synthes sales manager broke noncompete

June 13, 2014 by Brad Perriello

A federal judge rules that former Synthes sales rep John Marotta broke a non-compete agreement when he helped form and lead Emerge Medical.

Judge: Ex-Synthes rep broke noncompete

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Zimmer, Abbott, others rake in hundreds of millions in fed contracts

September 26, 2013 by Arezu Sarvestani

A slate of medical device makers, including Becton Dickinson, Johnson & Johnson and Zoll, land federal contracts collectively worth nearly $370 million.

Zimmer, Abbott, others rake in hundreds of millions in fed contracts

Federal agencies have handed out a slew of contracts and contract extensions in recent weeks, including about $370 million in deals for medical supplies and devices.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

MassDevice.com +7 | The top 7 med-tech stories for the week of June 15, 2013

June 14, 2013 by Brad Perriello

Plus Seven

Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com's coverage highlights our seven biggest and most influential stories from the week's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

When conduct becomes a crime

June 11, 2013 by MassDevice staff

FDA's official blog brought to you from FDA's senior leadership and staff stationed at home and abroad - sharing news, background, announcements and other information about the work done at the FDA on behalf of the American public.

John Roth

By: John Roth

In my last post, I explained how FDA's Office of Criminal Investigation (OCI) works when a small portion of the industry fails to adequately respond to regulatory action. For Abbott Laboratories and Amgen, the price for regulatory malfeasance was high:  $1.4 billion – yes, billion – paid in criminal and civil penalties to the United States. 

Synthes warns of fragmentation risk with soft tissue retractor

May 14, 2013 by Sony Salzman

Johnson & Johnson's Synthes subsidiary warns of the risk that 1 of its soft tissue retractors might fragment during use.

Hong Kong's Medical Device Control Office said Johnson & Johnson's (NYSE:JNJ) Synthes division issued a warning about the risk of injury from 1 of its soft tissue retractors.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Medical device earnings: Johnson & Johnson sees declines in several medtech divisions

April 16, 2013 by Arezu Sarvestani

Wall Street analysts worry that there may be larger negative trends for the industry as Johnson & Johnson reports declines in some of its medical device businesses.

Johnson & Johnson logo

Healthcare titan Johnson & Johnson (NYSE:JNJ) scored some hits and misses with Wall Street upon releasing its 1st-quarter 2013 earnings report, touting a 10% overall increase in medical devices and diagnostics revenues but failing to thrill analysts.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Medical Device Companies: Medtech's best/worst valued stocks

August 27, 2012 by MassDevice staff

A comparison of asset values and share values for medical device companies from the MassDevice Big 100 database.

MassDevice.com Big 100

One way to assess stock values is to compare the stock's share price with its asset value.

The latter is the number of shares outstanding divided into total assets. When the result is compared with share prices, it can help investors decide whether a stock is over- or under-valued.

We took a look at the asset values for 15 of the world's largest pure-play medical device companies and then compared them with the companies' stock price.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp